Cargando…

Efficacy of Modified Treat-and-Extend Regimen of Aflibercept for Macular Edema from Branch Retinal Vein Occlusion: 2-Year Prospective Study Outcomes

This study aimed to evaluate the long-term (24-month) efficacy and safety of a modified treat-and-extend (mTAE) regimen of aflibercept for macular edema (ME) due to branch retinal vein occlusion (BRVO). This was a prospective multicenter intervention study. We evaluated 50 eyes in 50 patients with M...

Descripción completa

Detalles Bibliográficos
Autores principales: Arai, Yusuke, Takahashi, Hidenori, Inoda, Satoru, Sakamoto, Shinichi, Tan, Xue, Inoue, Yuji, Tominaga, Satoko, Kawashima, Hidetoshi, Yanagi, Yasuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307685/
https://www.ncbi.nlm.nih.gov/pubmed/34300328
http://dx.doi.org/10.3390/jcm10143162
_version_ 1783728106496851968
author Arai, Yusuke
Takahashi, Hidenori
Inoda, Satoru
Sakamoto, Shinichi
Tan, Xue
Inoue, Yuji
Tominaga, Satoko
Kawashima, Hidetoshi
Yanagi, Yasuo
author_facet Arai, Yusuke
Takahashi, Hidenori
Inoda, Satoru
Sakamoto, Shinichi
Tan, Xue
Inoue, Yuji
Tominaga, Satoko
Kawashima, Hidetoshi
Yanagi, Yasuo
author_sort Arai, Yusuke
collection PubMed
description This study aimed to evaluate the long-term (24-month) efficacy and safety of a modified treat-and-extend (mTAE) regimen of aflibercept for macular edema (ME) due to branch retinal vein occlusion (BRVO). This was a prospective multicenter intervention study. We evaluated 50 eyes in 50 patients with ME due to BRVO enrolled between October 2016 and September 2017. The patients received intravitreal aflibercept (IVA) injections according to a mTAE regimen for 24 months. This study reports the secondary endpoints of best-corrected visual acuity (BCVA) and central subfield thickness (CST) at 24 months and compares them with previously reported primary endpoints. Compared with baseline BCVA and CST of 0.33 (0.27) and 488 (165) µm (mean (standard deviation)), respectively, BCVA and CST were significantly improved at 12 and 24 months (12 months: 0.059 (0.19) LogMAR and 299 (112) µm; 24 months: 0.034 (0.18) LogMAR and 272 (81) µm, respectively; both p < 0.0001). Over the 24-month period, the mean number of IVA injections and clinic visits was 7.4 (3.3) and 11.1 (2.0), respectively. The mTAE regimen of IVA injections for ME due to BRVO was effective for improving BCVA and reducing CST over 24 months. This regimen shows promise for reducing the number of injections and clinic visits.
format Online
Article
Text
id pubmed-8307685
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83076852021-07-25 Efficacy of Modified Treat-and-Extend Regimen of Aflibercept for Macular Edema from Branch Retinal Vein Occlusion: 2-Year Prospective Study Outcomes Arai, Yusuke Takahashi, Hidenori Inoda, Satoru Sakamoto, Shinichi Tan, Xue Inoue, Yuji Tominaga, Satoko Kawashima, Hidetoshi Yanagi, Yasuo J Clin Med Article This study aimed to evaluate the long-term (24-month) efficacy and safety of a modified treat-and-extend (mTAE) regimen of aflibercept for macular edema (ME) due to branch retinal vein occlusion (BRVO). This was a prospective multicenter intervention study. We evaluated 50 eyes in 50 patients with ME due to BRVO enrolled between October 2016 and September 2017. The patients received intravitreal aflibercept (IVA) injections according to a mTAE regimen for 24 months. This study reports the secondary endpoints of best-corrected visual acuity (BCVA) and central subfield thickness (CST) at 24 months and compares them with previously reported primary endpoints. Compared with baseline BCVA and CST of 0.33 (0.27) and 488 (165) µm (mean (standard deviation)), respectively, BCVA and CST were significantly improved at 12 and 24 months (12 months: 0.059 (0.19) LogMAR and 299 (112) µm; 24 months: 0.034 (0.18) LogMAR and 272 (81) µm, respectively; both p < 0.0001). Over the 24-month period, the mean number of IVA injections and clinic visits was 7.4 (3.3) and 11.1 (2.0), respectively. The mTAE regimen of IVA injections for ME due to BRVO was effective for improving BCVA and reducing CST over 24 months. This regimen shows promise for reducing the number of injections and clinic visits. MDPI 2021-07-17 /pmc/articles/PMC8307685/ /pubmed/34300328 http://dx.doi.org/10.3390/jcm10143162 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Arai, Yusuke
Takahashi, Hidenori
Inoda, Satoru
Sakamoto, Shinichi
Tan, Xue
Inoue, Yuji
Tominaga, Satoko
Kawashima, Hidetoshi
Yanagi, Yasuo
Efficacy of Modified Treat-and-Extend Regimen of Aflibercept for Macular Edema from Branch Retinal Vein Occlusion: 2-Year Prospective Study Outcomes
title Efficacy of Modified Treat-and-Extend Regimen of Aflibercept for Macular Edema from Branch Retinal Vein Occlusion: 2-Year Prospective Study Outcomes
title_full Efficacy of Modified Treat-and-Extend Regimen of Aflibercept for Macular Edema from Branch Retinal Vein Occlusion: 2-Year Prospective Study Outcomes
title_fullStr Efficacy of Modified Treat-and-Extend Regimen of Aflibercept for Macular Edema from Branch Retinal Vein Occlusion: 2-Year Prospective Study Outcomes
title_full_unstemmed Efficacy of Modified Treat-and-Extend Regimen of Aflibercept for Macular Edema from Branch Retinal Vein Occlusion: 2-Year Prospective Study Outcomes
title_short Efficacy of Modified Treat-and-Extend Regimen of Aflibercept for Macular Edema from Branch Retinal Vein Occlusion: 2-Year Prospective Study Outcomes
title_sort efficacy of modified treat-and-extend regimen of aflibercept for macular edema from branch retinal vein occlusion: 2-year prospective study outcomes
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307685/
https://www.ncbi.nlm.nih.gov/pubmed/34300328
http://dx.doi.org/10.3390/jcm10143162
work_keys_str_mv AT araiyusuke efficacyofmodifiedtreatandextendregimenofafliberceptformacularedemafrombranchretinalveinocclusion2yearprospectivestudyoutcomes
AT takahashihidenori efficacyofmodifiedtreatandextendregimenofafliberceptformacularedemafrombranchretinalveinocclusion2yearprospectivestudyoutcomes
AT inodasatoru efficacyofmodifiedtreatandextendregimenofafliberceptformacularedemafrombranchretinalveinocclusion2yearprospectivestudyoutcomes
AT sakamotoshinichi efficacyofmodifiedtreatandextendregimenofafliberceptformacularedemafrombranchretinalveinocclusion2yearprospectivestudyoutcomes
AT tanxue efficacyofmodifiedtreatandextendregimenofafliberceptformacularedemafrombranchretinalveinocclusion2yearprospectivestudyoutcomes
AT inoueyuji efficacyofmodifiedtreatandextendregimenofafliberceptformacularedemafrombranchretinalveinocclusion2yearprospectivestudyoutcomes
AT tominagasatoko efficacyofmodifiedtreatandextendregimenofafliberceptformacularedemafrombranchretinalveinocclusion2yearprospectivestudyoutcomes
AT kawashimahidetoshi efficacyofmodifiedtreatandextendregimenofafliberceptformacularedemafrombranchretinalveinocclusion2yearprospectivestudyoutcomes
AT yanagiyasuo efficacyofmodifiedtreatandextendregimenofafliberceptformacularedemafrombranchretinalveinocclusion2yearprospectivestudyoutcomes